Noa Therapeutics secures pre-Seed financing to transform the treatment of inflammatory disease

Noa Therapeutics, a preclinical stage biotech company with a portfolio of novel trimodal therapeutics to address inflammatory barrier diseases, secured an oversubscribed pre-Seed financing round. The round was led by UCeed, with participation inclusive of Ontario Centre of Innovation Life Science Innovation Fund, Archangel Network's StarForge and Phoenix Fire funds, Golden Triangle Angel Network, Angel One Investor Network, and NorthSpring Capital Partners. The financing round is inclusive of 58% of investment diligence led by women and 27% direct dilutive investment by women.

Noa Therapeutics is an OBIO® member, an alumnus of our BDSP™, H2BB™ and WiHI programs, and presented at the OBIO® Investment Summit.